Skip to main content
Keith McCrae, MD, Oncology, Cleveland, OH

Keith R McCrae MD

Hematologic Oncology


Director, Benign Hematology, Professor of Molecular Medicine, Cleveland Clinic

Join to View Full Profile
  • 11100 Euclid AveCleveland, OH 44106

  • Phone+1 216-844-8500

  • Fax+1 216-286-6341

Dr. McCrae is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1985 - 1988
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1982 - 1985
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1982
  • Dartmouth College
    Dartmouth CollegeBA, Summa Cum Laude, 1978

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1999 - 2026
  • PA State Medical License
    PA State Medical License 1985 - 2002
  • NC State Medical License
    NC State Medical License 1982 - 1985
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
  • CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
  • CMS Meaningful Use Stage Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura  
    Scully M, Cataland SR, Peyvandi F, Coppo P, Kn�bl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES ..., NEJM, 1/1/2019
  • Duration of anticoagulant therapy and VTE recurrence in patients with cancer  
    Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Lalibert� F, Crivera C, Lefebvre P, Schein J., Supportive Care Cancer, 1/1/2019
  • Plasma Kallikrein Structure Reveals Apple Domain Disc Rotated Conformation Compared to Factor XI  
    Li C, Voos KM, Pathak M, Hall G, McCrae KR, Dreveny I, Li R, Emsley J., J. Thromb Haemost, 1/1/2019

Books/Book Chapters

Abstracts/Posters

  • The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey
    Keith R McCrae, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Characterization of Recombinant _2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography
    Keith R McCrae, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice
    Keith R McCrae, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Extracellular vesicles in cancer-associated thrombosis 
    Evans Center, Boston University School of Medicine, Boston MA - 1/1/2019
  • Pomalidomide in Hereditary Hemorrhagic Telangiectasia 
    San Juan, PRI - 1/1/2019
  • Special Symposium on the Basic Science of Hemostasis and Thrombosis 
    60th American Society of Hematology Annual Meeting - 12/3/2018

Press Mentions

  • Cleveland Clinic Trial Shows Promise in Treating Bleeding Disorder
    Cleveland Clinic Trial Shows Promise in Treating Bleeding DisorderSeptember 20th, 2024
  • Cure HHT's Advocacy Effort, Support Helps NIH-Sponsored PATH Trial Become First Successful, Large-Scale Randomized Trial for HHT
    Cure HHT's Advocacy Effort, Support Helps NIH-Sponsored PATH Trial Become First Successful, Large-Scale Randomized Trial for HHTSeptember 19th, 2024
  • Cancer Drug Shows Promise for Treating Rare Bleeding Disorder
    Cancer Drug Shows Promise for Treating Rare Bleeding DisorderSeptember 18th, 2024

Grant Support

  • Mechanisms of cancer immunotherapy-associated thrombosisCLEVELAND CLINIC LERNER COM-CWRU2023–2027
  • 1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)CLEVELAND CLINIC LERNER COM-CWRU2020–2025
  • Novel approaches to improve prediction of cancer-associated thrombosisCLEVELAND CLINIC LERNER COM-CWRU2018–2025
  • Regulation Of Angiogenesis By KininogenNational Heart, Lung, And Blood Institute2010–2012
  • Regulation Of Angiogenesis By KininogenNational Heart, Lung, And Blood Institute2009–2010

Other Languages

  • Spanish

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: